Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
140.64 +3.56 (+2.60%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 140.60 -0.04 (-0.03%) 19:30 ET
Profile for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Biogen Inc 225 BINNEY STREET CAMBRIDGE MA 02142 USA

www.biogen.com Employees: 7,605 P: 617-679-2000

Sector:

Medical

Description:

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

Key Statistics

Overview:

Market Capitalization, $K 20,586,180
Enterprise Value, $K 22,758,380
Shares Outstanding, K 146,375
Annual Sales, $ 9,676 M
Annual Net Income, $ 1,632 M
Last Quarter Sales, $ 2,455 M
Last Quarter Net Income, $ 266,700 K
EBIT, $ 2,696 M
EBITDA, $ 3,660 M
60-Month Beta -0.08
% of Insider Shareholders 0.16%
% of Institutional Shareholders 87.93%
Float, K 146,141
% Float 99.84%
Short Volume Ratio 0.41

Growth:

1-Year Return -36.39%
3-Year Return -32.18%
5-Year Return -54.40%
5-Year Revenue Growth -32.70%
5-Year Earnings Growth -50.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 3.44 on 02/12/25
Next Earnings Date N/A
Earnings Per Share ttm 16.47
EPS Growth vs. Prev Qtr -15.69%
EPS Growth vs. Prev Year 16.61%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 900-829 on 02/01/17

BIIB Ratios

Ratio
Price/Earnings ttm 8.32
Price/Earnings forward 8.66
Price/Earnings to Growth 1.47
Return-on-Equity % 14.98%
Return-on-Assets % 8.76%
Profit Margin % 16.87%
Debt/Equity 0.27
Price/Sales 2.07
Price/Cash Flow 5.93
Price/Book 1.20
Book Value/Share 114.71
Interest Coverage -1.73
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements